367 related articles for article (PubMed ID: 18292410)
1. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
[TBL] [Abstract][Full Text] [Related]
2. The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery.
Sørensen B; Asvaldsdottir HS; Gudmundsdottir BR; Onundarson PT
Thromb Res; 2009 Dec; 124(6):695-700. PubMed ID: 19733387
[TBL] [Abstract][Full Text] [Related]
3. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
5. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
Larsen OH; Stentoft J; Radia D; Ingerslev J; Sørensen B
Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the structural and mechanical effects of procoagulant agents on neonatal fibrin networks following cardiopulmonary bypass.
Nellenbach K; Guzzetta NA; Brown AC
J Thromb Haemost; 2018 Nov; 16(11):2159-2167. PubMed ID: 30182421
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
9. The in vitro effect of recombinant factor VIIa on coated platelet formation and clot dynamics of stored platelet concentrates.
Svendsen MS; Kristensen AT; Bochsen L; Salado-Jimena JA; Johansson PI
Transfusion; 2009 Oct; 49(10):2186-94. PubMed ID: 19527478
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U
Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065
[TBL] [Abstract][Full Text] [Related]
12. The utility of thromboelastography for guiding recombinant activated factor VII therapy for refractory hemorrhage after cardiac surgery.
Wasowicz M; Meineri M; McCluskey SM; Mitsakakis N; Karkouti K
J Cardiothorac Vasc Anesth; 2009 Dec; 23(6):828-34. PubMed ID: 19467888
[TBL] [Abstract][Full Text] [Related]
13. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
Sørensen B; Persson E; Ingerslev J
Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
15. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
[TBL] [Abstract][Full Text] [Related]
16. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
[TBL] [Abstract][Full Text] [Related]
17. Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy.
Ganter MT; Schmuck S; Hamiel CR; Wischmeyer PE; Heule D; Zollinger A; Hofer CK
J Cardiothorac Vasc Anesth; 2008 Oct; 22(5):675-80. PubMed ID: 18922422
[TBL] [Abstract][Full Text] [Related]
18. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
Fenger-Eriksen C; Tønnesen E; Ingerslev J; Sørensen B
Acta Anaesthesiol Scand; 2009 Mar; 53(3):332-8. PubMed ID: 19243319
[TBL] [Abstract][Full Text] [Related]
20. Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.
Tang M; Fenger-Eriksen C; Wierup P; Greisen J; Ingerslev J; Hjortdal V; Sørensen B
Thromb Res; 2017 Jun; 154():73-79. PubMed ID: 28437748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
